Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vaccination to prevent Mpox Infection (MPOX-VAX Study)
2023-507881-19-00Phase 4Authorised
- Sponsor
- University College Dublin
- Start
- Jun 2024
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, single-arm trial of JYNNEOS in mpox and smallpox, sponsored by University College Dublin. Primary endpoints: Mean geometric MVA-specific antibody titres at week 48 and Mean rate of change in MVA-specific antibody titres post week 6 to week 48. Planned start Jun 2024; status: authorised.
02
Drugs
JYNNEOS
03
Conditions
mpoxsmallpox
Beyond the preview
Go deeper on 2023-507881-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507881-19-00.